Pasithea Therapeutics(KTTA.US)

Last Updated 19:00:00 ET
longbridge loading

Pasithea Therapeutics Appoints Kartik Krishnan As CMO

rttnews·
US
KTTAW
-38.67%
US
KTTA
+3.29%
US
IXJ
+0.27%
rttnews·
US
KTTAW
-38.67%
US
KTTA
+3.29%
US
IXJ
+0.27%

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer | KTTA Stock News

StockTitan·
US
KTTAW
-38.67%
US
KTTA
+3.29%
US
LABU
+10.46%
StockTitan·
US
KTTAW
-38.67%
US
KTTA
+3.29%
US
LABU
+10.46%

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) | KTTA Stock News

StockTitan·
US
KTTAW
-38.67%
US
KTTA
+3.29%
US
FBT
+1.76%
StockTitan·
US
KTTAW
-38.67%
US
KTTA
+3.29%
US
FBT
+1.76%

MindBio Announces Closing of Private Placement

The newswire.ca·
US
NBSE.ESC
0.00%
US
BTMD
+6.58%
US
SBIO
+3.58%
The newswire.ca·
US
NBSE.ESC
0.00%
US
BTMD
+6.58%
US
SBIO
+3.58%

Pasithea Therapeutics | 10-K: FY2025 Revenue: USD 0

Earnings Watch·
US
KTTA
+3.29%
Earnings Watch·
US
KTTA
+3.29%

MindBio Announces Upsize to Private Placement up to $1.5 Million

The newswire.ca·
US
IBBQ
+2.21%
US
FBT
+1.76%
US
BIB
+4.03%
The newswire.ca·
US
IBBQ
+2.21%
US
FBT
+1.76%
US
BIB
+4.03%

MindBio to Raise Up to $650,000 for AI Intoxication Detection Expansion in Mining Sector

Tip Ranks·
US
KTTAW
-38.67%
US
KTTA
+3.29%
US
PBE
+1.37%
Tip Ranks·
US
KTTAW
-38.67%
US
KTTA
+3.29%
US
PBE
+1.37%
© 2026 Longbridge｜Disclaimer